Adam Keeney is the founder of NodThera. NodThera has raised $95M in total funding. Latest round: Series B. Backed by Sofinnova Partners, 5AM Ventures.
Adam Keeney is the CEO of NodThera, a clinical-stage biotechnology company focused on developing NLRP3 inflammasome inhibitors for chronic inflammatory diseases. Prior to his role at NodThera, he was the Global Head of Business Development at Sanofi Genzyme.
Full founder directory · Investor directory · Company funding database · Fundraising library